Drugs / DV-601
last change May 2011 re-read 2 minutes ago

DV-601

Vaccine

Developed for
chronic hepatitis B virus infection
Investigated by
Dynavax Technologies Corporation

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01023230 Sep 2009 → May 2011 chronic hepatitis B virus infection Dynavax Technologies Corporation Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DV-601 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01023230
Modality Vaccine “DV-601, an investigational, therapeutic vaccineNCT01023230